A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis – Full Text View – ClinicalTrials.gov

This is a promising phase I study combining ruxolitinib and selinexor for frontline therapy of myelofibrosis. So far 15 patients were dosed with acceptable toxicities and the initial data is presented in poster format at #ASCO22.

Read the full article here

Related Articles